small molecule

PEMETREXED

PEMETREXED DISODIUM

Loss of exclusivityMarch 2035latest FDA-listed patent expiry
CompanyShilpa MedicareView the full company profile on CliffBio

Drug detail

Brand namePEMETREXED
Active ingredientPEMETREXED DISODIUM
StrengthEQ 500MG/50ML BASE (10MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMay 2023
Marketing statusRX

Listed patents

PatentExpiresType
11147817March 2035product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found